A Two-part, Phase I, Open-label, Multicenter, Two-period, One-sequence Study to Investigate the Effect of Itraconazole and Rifampin on the PK of Vemurafenib at Steady State

Trial Profile

A Two-part, Phase I, Open-label, Multicenter, Two-period, One-sequence Study to Investigate the Effect of Itraconazole and Rifampin on the PK of Vemurafenib at Steady State

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Oct 2017

At a glance

  • Drugs Itraconazole (Primary) ; Rifampicin (Primary) ; Vemurafenib (Primary)
  • Indications Malignant melanoma
  • Focus Pharmacokinetics
  • Sponsors Genentech
  • Most Recent Events

    • 16 Mar 2017 Planned End Date changed from 1 Jan 2018 to 29 Nov 2018.
    • 16 Mar 2017 Planned primary completion date changed from 1 Jan 2018 to 29 Nov 2018.
    • 01 Jun 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top